Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T.

PLoS One. 2013 Jun 27;8(6):e67258. doi: 10.1371/journal.pone.0067258. Print 2013.

2.

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.

Fang DD, Cao J, Jani JP, Tsaparikos K, Blasina A, Kornmann J, Lira ME, Wang J, Jirout Z, Bingham J, Zhu Z, Gu Y, Los G, Hostomsky Z, Vanarsdale T.

Front Med. 2013 Dec;7(4):462-76. doi: 10.1007/s11684-013-0270-6. Epub 2013 Jul 2.

PMID:
23820871
3.

Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.

Michaud NR, Jani JP, Hillerman S, Tsaparikos KE, Barbacci-Tobin EG, Knauth E, Putz H Jr, Campbell M, Karam GA, Chrunyk B, Gebhard DF, Green LL, Xu JJ, Dunn MC, Coskran TM, Lapointe JM, Cohen BD, Coleman KG, Bedian V, Vincent P, Kajiji S, Steyn SJ, Borzillo GV, Los G.

MAbs. 2012 Nov-Dec;4(6):710-23. doi: 10.4161/mabs.22160. Epub 2012 Sep 24.

4.

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.

Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T.

Mol Cancer Ther. 2010 Jun;9(6):1618-28. doi: 10.1158/1535-7163.MCT-10-0034. Epub 2010 Jun 8.

5.

PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.

Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, Rossi AM, Steyn SJ, Su C, Tsaparikos K, Wishka D, Yoon K, Jakubczak JL.

Mol Cancer Ther. 2010 Apr;9(4):883-94. doi: 10.1158/1535-7163.MCT-09-0915. Epub 2010 Mar 30.

6.

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.

Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK.

Cancer Res. 2007 Oct 15;67(20):9887-93.

7.

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.

Cancer Res. 2003 Nov 1;63(21):7301-9.

8.

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, Miller PE, Boscoe BP, Cox ED, Iwata KK, Jani JP, Provoncha K, Kath JC, Liu Z, Moyer JD.

Cancer Res. 2003 Aug 1;63(15):4450-9.

9.

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.

Clin Cancer Res. 1998 Aug;4(8):1887-98.

10.

CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.

Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA.

Int J Cancer. 1997 Aug 7;72(4):673-9.

11.

Modulation of cisplatin sensitivity and accumulation by interferon alpha-2A in human squamous carcinoma cell lines.

Gupta V, Jani JP, Emerson EO, Xu BH, Scalamogna D, Xia H, Katoh A, Zaren HA, Singh SV.

Int J Cancer. 1995 Nov 3;63(3):419-22.

PMID:
7591242
12.

Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.

Singh SV, Xu BH, Gupta V, Emerson EO, Zaren HA, Jani JP.

Cancer Lett. 1995 Aug 16;95(1-2):49-56.

PMID:
7656243
13.

Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line.

Singh SV, Xu BH, Jani JP, Emerson EO, Backes MG, Rihn C, Scalamogna D, Stemmler N, Specht S, Blanock K, et al.

Int J Cancer. 1995 May 4;61(3):431-6.

PMID:
7729958
14.

Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine.

Gupta V, Jani JP, Jacobs S, Levitt M, Fields L, Awasthi S, Xu BH, Sreevardhan M, Awasthi YC, Singh SV.

Cancer Chemother Pharmacol. 1995;36(1):13-9.

PMID:
7720170
15.

Desensitization of 5HT2 receptors by protein kinase C activation in distal pulmonary vascular smooth muscle cells in culture.

Weng W, Reynolds IJ, Jani JP, Blaskovich M, Sebti SM, Davies P, Pitt BR.

Microcirculation. 1994 Jul;1(2):129-35.

PMID:
8790584
16.

Assessment of indoor exposure to polycyclic aromatic hydrocarbons for urban poor using various types of cooking fuels.

Raiyani CV, Jani JP, Desai NM, Shah SH, Shah PG, Kashyap SK.

Bull Environ Contam Toxicol. 1993 May;50(5):757-63. No abstract available.

PMID:
8490282
17.

Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis.

Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V, Katoh A.

Invasion Metastasis. 1993;13(6):314-24.

PMID:
7860224
18.

Neutralization of bleomycin hydrolase by an epitope-specific antibody.

Morris G, Mistry JS, Jani JP, Mignano JE, Sebti SM, Lazo JS.

Mol Pharmacol. 1992 Jul;42(1):57-62.

PMID:
1378925
19.

In vivo circumvention of human colon carcinoma resistance to bleomycin.

Jani JP, Mistry JS, Morris G, Davies P, Lazo JS, Sebti SM.

Cancer Res. 1992 May 15;52(10):2931-7.

20.

Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b.

Mistry JS, Jani JP, Morris G, Mujumdar RB, Reynolds IJ, Sebti SM, Lazo JS.

Cancer Res. 1992 Feb 1;52(3):709-18.

21.

In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64.

Jani JP, Mistry JS, Morris G, Lazo JS, Sebti SM.

Oncol Res. 1992;4(2):59-63.

PMID:
1375852
22.

Residues of organochlorine pesticides and polycyclic aromatic hydrocarbons in drinking water of Ahmedabad City, India.

Jani JP, Raiyani CV, Mistry JS, Patel JS, Desai NM, Kashyap SK.

Bull Environ Contam Toxicol. 1991 Sep;47(3):381-5. No abstract available.

PMID:
1768952
23.

Polycyclic aromatic hydrocarbons in traditional medicinal preparations.

Jani JP, Raiyani CV, Mistry JS, Kashyap SK.

Hum Exp Toxicol. 1991 Sep;10(5):347-50.

PMID:
1683548
24.

Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells.

Morris G, Mistry JS, Jani JP, Sebti SM, Lazo JS.

Biochem Pharmacol. 1991 Jun 1;41(11):1559-66.

PMID:
1710457
25.
26.

Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.

Sebti SM, Jani JP, Mistry JS, Gorelik E, Lazo JS.

Cancer Res. 1991 Jan 1;51(1):227-32.

27.

Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family.

Sebti SM, Mignano JE, Jani JP, Srimatkandada S, Lazo JS.

Biochemistry. 1989 Aug 8;28(16):6544-8.

PMID:
2477059
28.

Histological and pharmacological changes in vas deferens of rats exposed to hexachlorocyclohexane.

Gautam AK, Gandhi DN, Jani JP, Venkatakrishna-Bhatt H, Chowdhury AR.

Res Commun Chem Pathol Pharmacol. 1989 Mar;63(3):463-6.

PMID:
2471237
29.

Benzidine and its acetylated metabolites in the urine of workers exposed to Direct Black 38.

Dewan A, Jani JP, Patel JS, Gandhi DN, Variya MR, Ghodasara NB.

Arch Environ Health. 1988 Jul-Aug;43(4):269-72.

PMID:
3415352
30.

Levels of dichlorodiphenyltrichloroethane and hexachlorocyclohexane in human adipose tissue of the Indian population.

Jani JP, Patel JS, Shah MP, Variya MR, Shah YH, Gupta S, Kashyap S.

Scand J Work Environ Health. 1988 Jun;14(3):201-4.

31.

Polycyclic aromatic hydrocarbons in kajal and surma eye cosmetic preparations.

Jani JP, Raiyani CV, Desai NM, Kashyap SK.

Hum Toxicol. 1988 Mar;7(2):195-7.

PMID:
3378809
32.

Levels of organochlorine pesticides in human milk in Ahmedabad, India.

Jani JP, Patel JS, Shah MP, Gupta SK, Kashyap SK.

Int Arch Occup Environ Health. 1988;60(2):111-3.

PMID:
3346080
33.

Urinary excretion of benzidine in relation to the acetylator status of occupationally exposed subjects.

Dewan A, Jani JP, Shah KS, Kashyap SK.

Hum Toxicol. 1986 Mar;5(2):95-7.

PMID:
3957356
34.

Cardiac toxicity in pesticide formulators exposed to organophosphate insecticides.

Saiyed HN, Gupta SK, Jani JP, Kashyap SK.

Indian J Med Res. 1984 Oct;80:494-8. No abstract available.

PMID:
6532962
35.

Clinical effects and cholinesterase activity changes in workers exposed to Phorate (Thimet).

Kashyap SK, Jani JP, Saiyed HN, Gupta SK.

J Environ Sci Health B. 1984 Jun-Jul;19(4-5):479-89.

PMID:
6470423
36.

Health hazards in pesticide formulators exposed to a combination of pesticides.

Gupta SK, Jani JP, Saiyed HN, Kashyap SK.

Indian J Med Res. 1984 May;79:666-72. No abstract available.

PMID:
6511003
37.

Health risks in ultra-low-volume (ULV) aerial spray of malathion for mosquito control.

Gupta SK, Pandya MK, Jani JP, Kashyap SK.

J Environ Sci Health B. 1980;15(3):287-94.

PMID:
7381188
38.

Effect of lindane on antibody response to typhoid vaccine in weanling rats.

Dewan A, Gupta SK, Jani JP, Kashyap SK.

J Environ Sci Health B. 1980;15(4):395-402.

PMID:
6156966

Supplemental Content

Support Center